With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
A fixed-dose combination of dolutegravir plus abacavir/lamivudine proved virologically superior to once-daily ritonavir-boosted atazanavir plus tenofovir/emtricitabine, in a large study of women with HIV.
If an HIV-positive patient's viral load test results come back between 50 copies/mL and 200 copies/mL, consider retesting the same blood sample, Joseph Eron Jr., M.D., recommends. New study results suggest that the retest results may alter a clinicia...
When it comes to an HIV cure, what do we know now and what are the main areas of focus for future research? Irini Sereti, M.D., reviewed and analyzed the current strategies in cure research, during a presentation at IDWeek 2016 in New Orleans.
Here's a look at some of the noteworthy HIV research being presented at IDWeek 2016 in New Orleans from Oct. 25 to 30.
In this interview, Matthew Perkins, M.D., discusses the interest in post-treatment controllers -- people living with HIV who are able to control the virus for a period of time after stopping therapy -- and the first study such individuals.
With more than 20 approved HIV antiretrovirals in the United States, physicians have many options for their patients -- they can choose one of the "preferred" drug regimens or deviate from treatment guidelines entirely.
A new study finds significant health disparities between black and white men with HIV, even though these men had equal access to health care through the Veterans Administration (VA).
Women with HIV should receive not only the same antiretroviral therapy as men, but also clinical care tailored to their specific risk factors and health care goals, according to Kathleen Squires, M.D.
Researchers at IDWeek 2015 discussed the logistics of delivering antiretroviral therapy to all 37 million people living with HIV in the world and how to reach people during acute HIV infection.